Pubmed Feed

• A genetically encoded protein tag for control and quantitative imaging of CAR T cell therapy.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2023 Dec 6;31(12):3564-3578 Epub 2023 Nov 3; Authors: Lee IK, Sharma N, Noguera-Ortega E, Liousia M, Baroja ML, Etersque JM, Pham J, Sarkar S, Carreno BM, Linette GP, Puré E, Albelda SM, Sellmyer MA

• CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn.
  Nature reviews. Clinical oncology. 2023 Oct 30; Authors: Albelda SM

• Surgical Inflammation Alters Immune Response to Intraoperative Photodynamic Therapy.
  Cancer research communications. 2023 Sep;3(9):1810-1822 Epub 2023 Sep 11; Authors: Davis RW 4th, Klampatsa A, Cramer GM, Kim MM, Miller JM, Yuan M, Houser C, Snyder E, Putt M, Vinogradov SA, Albelda SM, Cengel KA, Busch TM

• Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors.
  Nature communications. 2023 Aug 22;14(1):5110; Authors: Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, Kopp M, Li Y, Pattada N, Zhong W, Guo W, Scholler J, Liousia M, Assenmacher CA, June CH, Albelda SM, Puré E

• Molecular Imaging in Precision-Cut Non-Small Cell Lung Cancer Slices.
  The Annals of thoracic surgery. 2023 Aug 10; Authors: Azari F, Kennedy GT, Chang A, Low P, Basil M, Planer J, Katzen J, Eruslanov E, Albelda S, Singhal S

• Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors.
  bioRxiv : the preprint server for biology. 2023 Aug 7; Authors: Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, Kopp M, Li Y, Pattada N, Zhong W, Guo W, Scholler J, Liousia M, Assenmacher CA, June CH, Albelda SM, Puré E

• Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2023 Aug 2;31(8):2309-2325 Epub 2023 Jun 12; Authors: Haas AR, Golden RJ, Litzky LA, Engels B, Zhao L, Xu F, Taraszka JA, Ramones M, Granda B, Chang WJ, Jadlowsky J, Shea KM, Runkle A, Chew A, Dowd E, Gonzalez V, Chen F, Liu X, Fang C, Jiang S, Davis MM, Sheppard NC, Zhao Y, Fraietta JA, Lacey SF, Plesa G, Melenhorst JJ, Mansfield K, Brogdon JL, Young RM, Albelda SM, June CH, Tanyi JL

• Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors.
  Cell reports. Medicine. 2023 Jun 20;4(6):101053 Epub 2023 May 23; Authors: Jung IY, Noguera-Ortega E, Bartoszek R, Collins SM, Williams E, Davis M, Jadlowsky JK, Plesa G, Siegel DL, Chew A, Levine BL, Berger SL, Moon EK, Albelda SM, Fraietta JA

• Monitoring Therapeutic Response to Anti-FAP CAR T Cells Using [18F]AlF-FAPI-74.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 Dec 15;28(24):5330-5342; Authors: Lee IK, Noguera-Ortega E, Xiao Z, Todd L, Scholler J, Song D, Liousia M, Lohith K, Xu K, Edwards KJ, Farwell MD, June CH, Albelda SM, Puré E, Sellmyer MA

• Synthetic Secoisolariciresinol Diglucoside (LGM2605) Prevents Asbestos-Induced Inflammation and Genotoxic Cell Damage in Human Mesothelial Cells.
  International journal of molecular sciences. 2022 Sep 3;23(17); Authors: Pietrofesa RA, Chatterjee S, Kadariya Y, Testa JR, Albelda SM, Christofidou-Solomidou M

• Na(+)/H(+)-exchanger 1 enhances antitumor activity of engineered NK-92 natural killer cells.
  Cancer research communications. 2022 Aug;2(8):842-856 Epub 2022 Aug 22; Authors: Gong YY, Shao H, Li Y, Brafford P, Stine ZE, Sun J, Felsher DW, Orange JS, Albelda SM, Dang CV

• CAR T cells produced in vivo to treat cardiac injury.
  Science (New York, N.Y.). 2022 Jan 7;375(6576):91-96 Epub 2022 Jan 6; Authors: Rurik JG, Tombácz I, Yadegari A, Méndez Fernández PO, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, Mui BL, Albelda SM, Puré E, June CH, Aghajanian H, Weissman D, Parhiz H, Epstein JA

• An NK-like CAR T cell transition in CAR T cell dysfunction.
  Cell. 2021 Dec 9;184(25):6081-6100.e26 Epub 2021 Dec 2; Authors: Good CR, Aznar MA, Kuramitsu S, Samareh P, Agarwal S, Donahue G, Ishiyama K, Wellhausen N, Rennels AK, Ma Y, Tian L, Guedan S, Alexander KA, Zhang Z, Rommel PC, Singh N, Glastad KM, Richardson MW, Watanabe K, Tanyi JL, O'Hara MH, Ruella M, Lacey SF, Moon EK, Schuster SJ, Albelda SM, Lanier LL, Young RM, Berger SL, June CH

• A human CD137×PD-L1 bispecific antibody promotes anti-tumor immunity via context-dependent T cell costimulation and checkpoint blockade.
  Nature communications. 2021 Jul 21;12(1):4445; Authors: Geuijen C, Tacken P, Wang LC, Klooster R, van Loo PF, Zhou J, Mondal A, Liu YB, Kramer A, Condamine T, Volgina A, Hendriks LJA, van der Maaden H, Rovers E, Engels S, Fransen F, den Blanken-Smit R, Zondag-van der Zande V, Basmeleh A, Bartelink W, Kulkarni A, Marissen W, Huang CY, Hall L, Harvey S, Kim S, Martinez M, O'Brien S, Moon E, Albelda S, Kanellopoulou C, Stewart S, Nastri H, Bakker ABH, Scherle P, Logtenberg T, Hollis G, de Kruif J, Huber R, Mayes PA, Throsby M

• Mesothelin-targeted CAR-T cell therapy for solid tumors.
  Expert opinion on biological therapy. 2021 Apr;21(4):473-486 Epub 2020 Nov 12; Authors: Klampatsa A, Dimou V, Albelda SM

• Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
  Lung cancer (Amsterdam, Netherlands). 2021 Apr;154:5-12 Epub 2021 Jan 14; Authors: Katz SI, Roshkovan L, Berger I, Friedberg JS, Alley EW, Simone CB 2nd, Haas AR, Cengel KA, Sterman DH, Albelda SM

• Neoadjuvant Gene-Mediated Cytotoxic Immunotherapy for Non-Small-Cell Lung Cancer: Safety and Immunologic Activity.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2021 Feb 3;29(2):658-670 Epub 2020 Nov 5; Authors: Predina JD, Haas AR, Martinez M, O'Brien S, Moon EK, Woodruff P, Stadanlick J, Corbett C, Frenzel-Sulyok L, Bryski MG, Eruslanov E, Deshpande C, Langer C, Aguilar LK, Guzik BW, Manzanera AG, Aguilar-Cordova E, Singhal S, Albelda SM

• Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma.
  Journal for immunotherapy of cancer. 2020 Oct;8(2); Authors: Thompson JC, Davis C, Deshpande C, Hwang WT, Jeffries S, Huang A, Mitchell TC, Langer CJ, Albelda SM

• Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2020 Aug 5;28(8):1932 Epub 2020 Jul 21; Authors: Richman SA, Wang LC, Moon EK, Khire UR, Albelda SM, Milone MC

• Analysis and Augmentation of the Immunologic Bystander Effects of CAR T Cell Therapy in a Syngeneic Mouse Cancer Model.
  Molecular therapy oncolytics. 2020 Sep 25;18:360-371 Epub 2020 Jul 15; Authors: Klampatsa A, Leibowitz MS, Sun J, Liousia M, Arguiri E, Albelda SM

• Ligand-Induced Degradation of a CAR Permits Reversible Remote Control of CAR T Cell Activity In Vitro and In Vivo.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2020 Jul 8;28(7):1600-1613 Epub 2020 Jun 11; Authors: Richman SA, Wang LC, Moon EK, Khire UR, Albelda SM, Milone MC

• 4-1BB costimulation promotes CAR T cell survival through noncanonical NF-κB signaling.
  Science signaling. 2020 Mar 31;13(625); Authors: Philipson BI, O'Connor RS, May MJ, June CH, Albelda SM, Milone MC

• Tumor Antigen Heterogeneity: The "Elephant in the Room" of Adoptive T-cell Therapy for Solid Tumors.
  Cancer immunology research. 2020 Jan;8(1):2; Authors: Albelda SM

• Current Advances in CAR T Cell Therapy for Malignant Mesothelioma.
  Journal of cellular immunology. 2020;2(4):192-200; Authors: Klampatsa A, Albelda SM

• Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy.
  Lung cancer (Amsterdam, Netherlands). 2020 Jan;139:1-8 Epub 2019 Oct 18; Authors: Thompson JC, Hwang WT, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, Krishna V, Smirnov D, Verona R, Lorenzi MV, Langer CJ, Albelda SM

• Neutrophil content predicts lymphocyte depletion and anti-PD1 treatment failure in NSCLC.
  JCI insight. 2019 Dec 19;4(24); Authors: Kargl J, Zhu X, Zhang H, Yang GHY, Friesen TJ, Shipley M, Maeda DY, Zebala JA, McKay-Fleisch J, Meredith G, Mashadi-Hossein A, Baik C, Pierce RH, Redman MW, Thompson JC, Albelda SM, Bolouri H, Houghton AM

• Author Correction: Targeting cardiac fibrosis with engineered T cells.
  Nature. 2019 Dec;576(7785):E2; Authors: Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, Wang T, Bedi K, Morley MP, Saldana RAL, Bolar NA, McDaid K, Assenmacher CA, Smith CL, Wirth D, June CH, Margulies KB, Jain R, Puré E, Albelda SM, Epstein JA

• Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2019 Nov 6;27(11):1919-1929 Epub 2019 Jul 30; Authors: Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL

• Targeting cardiac fibrosis with engineered T cells.
  Nature. 2019 Sep;573(7774):430-433 Epub 2019 Sep 11; Authors: Aghajanian H, Kimura T, Rurik JG, Hancock AS, Leibowitz MS, Li L, Scholler J, Monslow J, Lo A, Han W, Wang T, Bedi K, Morley MP, Linares Saldana RA, Bolar NA, McDaid K, Assenmacher CA, Smith CL, Wirth D, June CH, Margulies KB, Jain R, Puré E, Albelda SM, Epstein JA

• Loss of cells expressing fibroblast activation protein has variable effects in models of TGF-β and chronic bleomycin-induced fibrosis.
  American journal of physiology. Lung cellular and molecular physiology. 2019 Aug 1;317(2):L271-L282 Epub 2019 Jun 12; Authors: Kimura T, Monslow J, Klampatsa A, Leibowitz M, Sun J, Liousia M, Woodruff P, Moon E, Todd L, Puré E, Albelda SM

• Synthetic secoisolariciresinol diglucoside (LGM2605) inhibits Libby amphibole fiber-induced acute inflammation in mice.
  Toxicology and applied pharmacology. 2019 Jul 15;375:81-93 Epub 2019 Apr 23; Authors: Christofidou-Solomidou M, Pietrofesa RA, Park K, Albelda SM, Serve KM, Keil DE, Pfau JC

• Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes.
  Oncoimmunology. 2019;8(9):e1638211 Epub 2019 Jul 13; Authors: Klampatsa A, O'Brien SM, Thompson JC, Rao AS, Stadanlick JE, Martinez MC, Liousia M, Cantu E, Cengel K, Moon EK, Singhal S, Eruslanov EB, Albelda SM

• Function of Human Tumor-Infiltrating Lymphocytes in Early-Stage Non-Small Cell Lung Cancer.
  Cancer immunology research. 2019 Jun;7(6):896-909 Epub 2019 May 3; Authors: O'Brien SM, Klampatsa A, Thompson JC, Martinez MC, Hwang WT, Rao AS, Standalick JE, Kim S, Cantu E, Litzky LA, Singhal S, Eruslanov EB, Moon EK, Albelda SM

• Human tumor-associated monocytes/macrophages and their regulation of T cell responses in early-stage lung cancer.
  Science translational medicine. 2019 Feb 13;11(479); Authors: Singhal S, Stadanlick J, Annunziata MJ, Rao AS, Bhojnagarwala PS, O'Brien S, Moon EK, Cantu E, Danet-Desnoyers G, Ra HJ, Litzky L, Akimova T, Beier UH, Hancock WW, Albelda SM, Eruslanov EB

• Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy.
  Photochemistry and photobiology. 2019 Jan;95(1):430-438 Epub 2018 Nov 26; Authors: Davis RW 4th, Snyder E, Miller J, Carter S, Houser C, Klampatsa A, Albelda SM, Cengel KA, Busch TM

• Molecular Characterization of Malignant Mesothelioma: Time for New Targets?
  Cancer discovery. 2018 Dec;8(12):1508-1510; Authors: Aggarwal C, Albelda SM

• A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.
  Lasers in surgery and medicine. 2018 Jul;50(5):440-450 Epub 2018 May 25; Authors: Davis RW 4th, Papasavvas E, Klampatsa A, Putt M, Montaner LJ, Culligan MJ, McNulty S, Friedberg JS, Simone CB 2nd, Singhal S, Albelda SM, Cengel KA, Busch TM

• Epigenomic-Guided Mass Cytometry Profiling Reveals Disease-Specific Features of Exhausted CD8 T Cells.
  Immunity. 2018 May 15;48(5):1029-1045.e5; Authors: Bengsch B, Ohtani T, Khan O, Setty M, Manne S, O'Brien S, Gherardini PF, Herati RS, Huang AC, Chang KM, Newell EW, Bovenschen N, Pe'er D, Albelda SM, Wherry EJ

• Phase I Study of Intrapleural Gene-Mediated Cytotoxic Immunotherapy in Patients with Malignant Pleural Effusion.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2018 May 2;26(5):1198-1205 Epub 2018 Feb 21; Authors: Aggarwal C, Haas AR, Metzger S, Aguilar LK, Aguilar-Cordova E, Manzanera AG, Gómez-Hernández G, Katz SI, Alley EW, Evans TL, Bauml JM, Cohen RB, Langer CJ, Albelda SM, Sterman DH

• Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605) Reduces Asbestos-Induced Cytotoxicity in an Nrf2-Dependent and -Independent Manner.
  Antioxidants (Basel, Switzerland). 2018 Mar 2;7(3); Authors: Pietrofesa RA, Chatterjee S, Park K, Arguiri E, Albelda SM, Christofidou-Solomidou M

• Novel therapies for malignant pleural mesothelioma.
  The Lancet. Oncology. 2018 Mar;19(3):e161-e172; Authors: Scherpereel A, Wallyn F, Albelda SM, Munck C

• Human neutrophils can mimic myeloid-derived suppressor cells (PMN-MDSC) and suppress microbead or lectin-induced T cell proliferation through artefactual mechanisms.
  Scientific reports. 2018 Feb 16;8(1):3135; Authors: Negorev D, Beier UH, Zhang T, Quatromoni JG, Bhojnagarwala P, Albelda SM, Singhal S, Eruslanov E, Lohoff FW, Levine MH, Diamond JM, Christie JD, Hancock WW, Akimova T

• Intra-tumoral delivery of CXCL11 via a vaccinia virus, but not by modified T cells, enhances the efficacy of adoptive T cell therapy and vaccines.
  Oncoimmunology. 2018;7(3):e1395997 Epub 2018 Jan 9; Authors: Moon EK, Wang LS, Bekdache K, Lynn RC, Lo A, Thorne SH, Albelda SM

• Circulating tumor cells as a predictive biomarker in patients with small cell lung cancer undergoing chemotherapy.
  Lung cancer (Amsterdam, Netherlands). 2017 Oct;112:118-125 Epub 2017 Aug 12; Authors: Aggarwal C, Wang X, Ranganathan A, Torigian D, Troxel A, Evans T, Cohen RB, Vaidya B, Rao C, Connelly M, Vachani A, Langer C, Albelda S

• Chimeric Antigen Receptor (CAR) T Cell Therapy for Malignant Pleural Mesothelioma (MPM).
  Cancers. 2017 Sep 1;9(9); Authors: Klampatsa A, Haas AR, Moon EK, Albelda SM

• Human lung tumor FOXP3+ Tregs upregulate four "Treg-locking" transcription factors.
  JCI insight. 2017 Aug 17;2(16); Authors: Akimova T, Zhang T, Negorev D, Singhal S, Stadanlick J, Rao A, Annunziata M, Levine MH, Beier UH, Diamond JM, Christie JD, Albelda SM, Eruslanov EB, Hancock WW

• The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System.
  Annals of the American Thoracic Society. 2017 Aug;14(8):1248-1260; Authors: Moon EK, Langer CJ, Albelda SM

• Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging.
  Oncotarget. 2017 Apr 11;8(15):24213-24223; Authors: Chen X, Yang Y, Berger I, Khalid U, Patel A, Cai J, Farwell MD, Langer C, Aggarwal C, Albelda SM, Katz SI

• Mouse versus Human Neutrophils in Cancer: A Major Knowledge Gap.
  Trends in cancer. 2017 Feb;3(2):149-160 Epub 2017 Jan 19; Authors: Eruslanov EB, Singhal S, Albelda SM

• CAR T Cell Therapy for Solid Tumors.
  Annual review of medicine. 2017 Jan 14;68:139-152 Epub 2016 Nov 17; Authors: Newick K, O'Brien S, Moon E, Albelda SM

• The Synthetic Lignan Secoisolariciresinol Diglucoside Prevents Asbestos-Induced NLRP3 Inflammasome Activation in Murine Macrophages.
  Oxidative medicine and cellular longevity. 2017;2017:7395238 Epub 2017 Sep 13; Authors: Pietrofesa RA, Woodruff P, Hwang WT, Patel P, Chatterjee S, Albelda SM, Christofidou-Solomidou M

• Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor Immunity.
  EBioMedicine. 2016 Nov;13:99-112 Epub 2016 Oct 15; Authors: Wang L, Kumar S, Dahiya S, Wang F, Wu J, Newick K, Han R, Samanta A, Beier UH, Akimova T, Bhatti TR, Nicholson B, Kodrasov MP, Agarwal S, Sterner DE, Gu W, Weinstock J, Butt TR, Albelda SM, Hancock WW

• Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer.
  Frontiers in cell and developmental biology. 2016;4:108 Epub 2016 Oct 17; Authors: Riese MJ, Moon EK, Johnson BD, Albelda SM

• Tumor-associated neutrophils display a distinct N1 profile following TGFβ modulation: A transcriptomics analysis of pro- vs. antitumor TANs.
  Oncoimmunology. 2016;5(11):e1232221 Epub 2016 Sep 13; Authors: Shaul ME, Levy L, Sun J, Mishalian I, Singhal S, Kapoor V, Horng W, Fridlender G, Albelda SM, Fridlender ZG

• Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Aug 1;22(15):3791-800 Epub 2016 Mar 11; Authors: Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, Heitjan DF, Hwang WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner LJ, Cengel KA, Simone CB 2nd, Culligan M, Langer CJ, Albelda SM

• Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.
  Science immunology. 2016 Aug;1(2) Epub 2016 Aug 5; Authors: Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, Malietzis G, Lee GH, Eruslanov E, Albelda SM, Wang X, Mehta JL, Bewtra M, Rustgi A, Hockstein N, Witt R, Masters G, Nam B, Smirnov D, Sepulveda MA, Gabrilovich DI

• Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer.
  Cancer cell. 2016 Jul 11;30(1):120-135 Epub 2016 Jun 30; Authors: Singhal S, Bhojnagarwala PS, O'Brien S, Moon EK, Garfall AL, Rao AS, Quatromoni JG, Stephen TL, Litzky L, Deshpande C, Feldman MD, Hancock WW, Conejo-Garcia JR, Albelda SM, Eruslanov EB

• Augmentation of CAR T-cell Trafficking and Antitumor Efficacy by Blocking Protein Kinase A Localization.
  Cancer immunology research. 2016 Jun;4(6):541-51 Epub 2016 Apr 4; Authors: Newick K, O'Brien S, Sun J, Kapoor V, Maceyko S, Lo A, Puré E, Moon E, Albelda SM

• Chimeric antigen receptor T-cell therapy for solid tumors.
  Molecular therapy oncolytics. 2016;3:16006 Epub 2016 Apr 13; Authors: Newick K, Moon E, Albelda SM

• Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605).
  International journal of molecular sciences. 2016 Mar 1;17(3):322; Authors: Pietrofesa RA, Velalopoulou A, Albelda SM, Christofidou-Solomidou M

• Flaxseed lignans enriched in secoisolariciresinol diglucoside prevent acute asbestos-induced peritoneal inflammation in mice.
  Carcinogenesis. 2016 Feb;37(2):177-87 Epub 2015 Dec 17; Authors: Pietrofesa RA, Velalopoulou A, Arguiri E, Menges CW, Testa JR, Hwang WT, Albelda SM, Christofidou-Solomidou M

• Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Jan 15;22(2):436-47 Epub 2015 Aug 31; Authors: Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O'Brien S, Lo A, Liu X, Zhao Y, Albelda SM

• Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models.
  ERJ open research. 2015 Oct;1(2) Epub 2015 Oct 19; Authors: Hubaux R, Vandermeers F, Cosse JP, Crisanti C, Kapoor V, Albelda SM, Mascaux C, Delvenne P, Hubert P, Willems L

• The Optical Biopsy: A Novel Technique for Rapid Intraoperative Diagnosis of Primary Pulmonary Adenocarcinomas.
  Annals of surgery. 2015 Oct;262(4):602-9; Authors: Kennedy GT, Okusanya OT, Keating JJ, Heitjan DF, Deshpande C, Litzky LA, Albelda SM, Drebin JA, Nie S, Low PS, Singhal S

• CD11b+Ly6G+ cells inhibit tumor growth by suppressing IL-17 production at early stages of tumorigenesis.
  Oncoimmunology. 2016;5(1):e1061175 Epub 2015 Jul 28; Authors: Liu Y, O'Leary CE, Wang LS, Bhatti TR, Dai N, Kapoor V, Liu P, Mei J, Guo L, Oliver PM, Albelda SM, Worthen GS

• Tumor-Promoting Desmoplasia Is Disrupted by Depleting FAP-Expressing Stromal Cells.
  Cancer research. 2015 Jul 15;75(14):2800-2810 Epub 2015 May 15; Authors: Lo A, Wang LS, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA, Bajor DJ, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Puré E

• Generation of Potent T-cell Immunotherapy for Cancer Using DAP12-Based, Multichain, Chimeric Immunoreceptors.
  Cancer immunology research. 2015 Jul;3(7):815-26 Epub 2015 May 4; Authors: Wang E, Wang LC, Tsai CY, Bhoj V, Gershenson Z, Moon E, Newick K, Sun J, Lo A, Baradet T, Feldman MD, Barrett D, Puré E, Albelda S, Milone MC

• Surgical cytoreduction restores the antitumor efficacy of a Listeria monocytogenes vaccine in malignant pleural mesothelioma.
  Immunology letters. 2015 Jul;166(1):28-35 Epub 2015 May 18; Authors: Kennedy GT, Judy BF, Bhojnagarwala P, Moon EK, Fridlender ZG, Albelda SM, Singhal S

• Promoting metastasis: neutrophils and T cells join forces.
  Cell research. 2015 Jul;25(7):765-6 Epub 2015 May 26; Authors: Fridlender ZG, Albelda SM, Granot Z

• An optimized disaggregation method for human lung tumors that preserves the phenotype and function of the immune cells.
  Journal of leukocyte biology. 2015 Jan;97(1):201-9 Epub 2014 Oct 30; Authors: Quatromoni JG, Singhal S, Bhojnagarwala P, Hancock WW, Albelda SM, Eruslanov E

• Bioanalytical techniques for detecting biomarkers of response to human asbestos exposure.
  Bioanalysis. 2015;7(9):1157-73; Authors: Mesaros C, Worth AJ, Snyder NW, Christofidou-Solomidou M, Vachani A, Albelda SM, Blair IA

• Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer.
  The Journal of clinical investigation. 2014 Dec;124(12):5466-80 Epub 2014 Nov 10; Authors: Eruslanov EB, Bhojnagarwala PS, Quatromoni JG, Stephen TL, Ranganathan A, Deshpande C, Akimova T, Vachani A, Litzky L, Hancock WW, Conejo-Garcia JR, Feldman M, Albelda SM, Singhal S

• Intraoperative near-infrared imaging can identify pulmonary nodules.
  The Annals of thoracic surgery. 2014 Oct;98(4):1223-30 Epub 2014 Aug 5; Authors: Okusanya OT, Holt D, Heitjan D, Deshpande C, Venegas O, Jiang J, Judy R, DeJesus E, Madajewski B, Oh K, Wang M, Albelda SM, Nie S, Singhal S

• Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17--a new mechanism of impaired antitumor immunity.
  International journal of cancer. 2014 Sep 1;135(5):1178-86 Epub 2014 Feb 27; Authors: Mishalian I, Bayuh R, Eruslanov E, Michaeli J, Levy L, Zolotarov L, Singhal S, Albelda SM, Granot Z, Fridlender ZG

• Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor-transduced human T cells in solid tumors.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2014 Aug 15;20(16):4262-73 Epub 2014 Jun 11; Authors: Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC, June CH, Riley JL, Wherry EJ, Albelda SM

• Intraoperative near-infrared imaging can distinguish cancer from normal tissue but not inflammation.
  PloS one. 2014;9(7):e103342 Epub 2014 Jul 29; Authors: Holt D, Okusanya O, Judy R, Venegas O, Jiang J, DeJesus E, Eruslanov E, Quatromoni J, Bhojnagarwala P, Deshpande C, Albelda S, Nie S, Singhal S

• Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
  Cancer immunology research. 2014 Feb;2(2):112-20; Authors: Beatty GL, Haas AR, Maus MV, Torigian DA, Soulen MC, Plesa G, Chew A, Zhao Y, Levine BL, Albelda SM, Kalos M, June CH

• Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity.
  Cancer immunology research. 2014 Feb;2(2):154-66 Epub 2013 Nov 12; Authors: Wang LC, Lo A, Scholler J, Sun J, Majumdar RS, Kapoor V, Antzis M, Cotner CE, Johnson LA, Durham AC, Solomides CC, June CH, Puré E, Albelda SM

• Giving oncolytic vaccinia virus more BiTE.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2014 Jan;22(1):6-8; Authors: Albelda SM, Thorne SH

• Use of circulating tumor cell technology (CELLSEARCH) for the diagnosis of malignant pleural effusions.
  Annals of the American Thoracic Society. 2013 Dec;10(6):582-9; Authors: Schwed Lustgarten DE, Thompson J, Yu G, Vachani A, Vaidya B, Rao C, Connelly M, Udine M, Tan KS, Heitjan DF, Albelda S

• Modifying tumor-associated macrophages: An important adjunct to immunotherapy.
  Oncoimmunology. 2013 Dec 1;2(12):e26620 Epub 2013 Oct 21; Authors: Fridlender ZG, Albelda SM

• Overcoming intrinsic inhibitory pathways to augment the antineoplastic activity of adoptively transferred T cells: Re-tuning your CAR before hitting a rocky road.
  Oncoimmunology. 2013 Nov 1;2(11):e26492 Epub 2013 Oct 10; Authors: Wang LC, Riese MJ, Moon EK, Albelda SM

• Thrombospondin-1 mediates oncogenic Ras-induced senescence in premalignant lung tumors.
  The Journal of clinical investigation. 2013 Oct;123(10):4375-89 Epub 2013 Sep 9; Authors: Baek KH, Bhang D, Zaslavsky A, Wang LC, Vachani A, Kim CF, Albelda SM, Evan GI, Ryeom S

• Inhibition of p300 impairs Foxp3⁺ T regulatory cell function and promotes antitumor immunity.
  Nature medicine. 2013 Sep;19(9):1173-7 Epub 2013 Aug 18; Authors: Liu Y, Wang L, Predina J, Han R, Beier UH, Wang LC, Kapoor V, Bhatti TR, Akimova T, Singhal S, Brindle PK, Cole PA, Albelda SM, Hancock WW

• Immunological effects of the TGFβ-blocking antibody GC1008 in malignant pleural mesothelioma patients.
  Oncoimmunology. 2013 Aug 1;2(8):e26218 Epub 2013 Aug 27; Authors: Stevenson JP, Kindler HL, Papasavvas E, Sun J, Jacobs-Small M, Hull J, Schwed D, Ranganathan A, Newick K, Heitjan DF, Langer CJ, McPherson JM, Montaner LJ, Albelda SM

• The timing of TGF-β inhibition affects the generation of antigen-specific CD8+ T cells.
  BMC immunology. 2013 Jul 17;14:30; Authors: Quatromoni JG, Suzuki E, Okusanya O, Judy BF, Bhojnagarwala P, Venegas O, Eruslanov E, Predina JD, Albelda SM, Singhal S

• T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.
  Cancer immunology research. 2013 Jul;1(1):26-31 Epub 2013 Apr 7; Authors: Maus MV, Haas AR, Beatty GL, Albelda SM, Levine BL, Liu X, Zhao Y, Kalos M, June CH

• Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases.
  Cancer research. 2013 Jun 15;73(12):3566-77 Epub 2013 Apr 10; Authors: Riese MJ, Wang LC, Moon EK, Joshi RP, Ranganathan A, June CH, Koretzky GA, Albelda SM

• Thymidylate synthase and folyl-polyglutamate synthase are not clinically useful markers of response to pemetrexed in patients with malignant pleural mesothelioma.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2013 Apr;8(4):469-77; Authors: Lustgarten DE, Deshpande C, Aggarwal C, Wang LC, Saloura V, Vachani A, Wang LP, Litzky L, Feldman M, Creaney J, Nowak AK, Langer C, Inghilleri S, Stella G, Albelda SM

• The receptor for advanced glycation end products mediates lung endothelial activation by RBCs.
  American journal of physiology. Lung cellular and molecular physiology. 2013 Feb 15;304(4):L250-63 Epub 2012 Dec 28; Authors: Mangalmurti NS, Friedman JL, Wang LC, Stolz D, Muthukumaran G, Siegel DL, Schmidt AM, Lee JS, Albelda SM

• Changes in the local tumor microenvironment in recurrent cancers may explain the failure of vaccines after surgery.
  Proceedings of the National Academy of Sciences of the United States of America. 2013 Jan 29;110(5):E415-24 Epub 2012 Dec 27; Authors: Predina J, Eruslanov E, Judy B, Kapoor V, Cheng G, Wang LC, Sun J, Moon EK, Fridlender ZG, Albelda S, Singhal S

• Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
  Science translational medicine. 2012 Oct 3;4(154):154ra134; Authors: Goncharova EA, Goncharov DA, Fehrenbach M, Khavin I, Ducka B, Hino O, Colby TV, Merrilees MJ, Haczku A, Albelda SM, Krymskaya VP

• Lower serum endocan levels are associated with the development of acute lung injury after major trauma.
  Journal of critical care. 2012 Oct;27(5):522.e11-7 Epub 2011 Sep 29; Authors: Mikkelsen ME, Shah CV, Scherpereel A, Lanken PN, Lassalle P, Bellamy SL, Localio AR, Albelda SM, Meyer NJ, Christie JD

• Cytoreduction surgery reduces systemic myeloid suppressor cell populations and restores intratumoral immunotherapy effectiveness.
  Journal of hematology & oncology. 2012 Jun 28;5:34; Authors: Predina JD, Kapoor V, Judy BF, Cheng G, Fridlender ZG, Albelda SM, Singhal S

• Mesothelin, a novel immunotherapy target for triple negative breast cancer.
  Breast cancer research and treatment. 2012 Jun;133(2):799-804 Epub 2012 Mar 15; Authors: Tchou J, Wang LC, Selven B, Zhang H, Conejo-Garcia J, Borghaei H, Kalos M, Vondeheide RH, Albelda SM, June CH, Zhang PJ

• Tumor-associated neutrophils: friend or foe?
  Carcinogenesis. 2012 May;33(5):949-55 Epub 2012 Mar 16; Authors: Fridlender ZG, Albelda SM

• Vascular endothelial-targeted therapy combined with cytotoxic chemotherapy induces inflammatory intratumoral infiltrates and inhibits tumor relapses after surgery.
  Neoplasia (New York, N.Y.). 2012 Apr;14(4):352-9; Authors: Judy BF, Aliperti LA, Predina JD, Levine D, Kapoor V, Thorpe PE, Albelda SM, Singhal S

• Treating tumors with a vaccinia virus expressing IFNβ illustrates the complex relationships between oncolytic ability and immunogenicity.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2012 Apr;20(4):736-48 Epub 2011 Oct 18; Authors: Wang LC, Lynn RC, Cheng G, Alexander E, Kapoor V, Moon EK, Sun J, Fridlender ZG, Isaacs SN, Thorne SH, Albelda SM

• Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils.
  PloS one. 2012;7(2):e31524 Epub 2012 Feb 14; Authors: Fridlender ZG, Sun J, Mishalian I, Singhal S, Cheng G, Kapoor V, Horng W, Fridlender G, Bayuh R, Worthen GS, Albelda SM

• Peripheral immune cell gene expression predicts survival of patients with non-small cell lung cancer.
  PloS one. 2012;7(3):e34392 Epub 2012 Mar 29; Authors: Kossenkov AV, Dawany N, Evans TL, Kucharczuk JC, Albelda SM, Showe LC, Showe MK, Vachani A

• Urinary volatile compounds as biomarkers for lung cancer.
  Bioscience, biotechnology, and biochemistry. 2012;76(4):679-84 Epub 2012 Apr 7; Authors: Hanai Y, Shimono K, Matsumura K, Vachani A, Albelda S, Yamazaki K, Beauchamp GK, Oka H

• A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.
  American journal of respiratory and critical care medicine. 2011 Dec 15;184(12):1395-9 Epub 2011 Jun 3; Authors: Sterman DH, Haas A, Moon E, Recio A, Schwed D, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Papasavvas E, Montaner LJ, Heitjan DF, Litzky L, Friedberg J, Culligan M, June CH, Carroll RG, Albelda SM

• Gene therapy for lung neoplasms.
  Clinics in chest medicine. 2011 Dec;32(4):865-85 Epub 2011 Oct 7; Authors: Vachani A, Moon E, Wakeam E, Haas AR, Sterman DH, Albelda SM

• Curcumin suppresses growth of mesothelioma cells in vitro and in vivo, in part, by stimulating apoptosis.
  Molecular and cellular biochemistry. 2011 Nov;357(1-2):83-94 Epub 2011 May 19; Authors: Wang Y, Rishi AK, Wu W, Polin L, Sharma S, Levi E, Albelda S, Pass HI, Wali A

• Activation of mitogen-activated protein kinases by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) plays an important role in macrophage stimulation.
  Biochemical pharmacology. 2011 Nov 1;82(9):1175-85 Epub 2011 Jul 26; Authors: Sun J, Wang LC, Fridlender ZG, Kapoor V, Cheng G, Ching LM, Albelda SM

• Progression of human bronchioloalveolar carcinoma to invasive adenocarcinoma is modeled in a transgenic mouse model of K-ras-induced lung cancer by loss of the TGF-β type II receptor.
  Cancer research. 2011 Nov 1;71(21):6665-75 Epub 2011 Sep 12; Authors: Borczuk AC, Sole M, Lu P, Chen J, Wilgus ML, Friedman RA, Albelda SM, Powell CA

• Resection of non-small cell lung cancers reverses tumor-induced gene expression changes in the peripheral immune system.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Sep 15;17(18):5867-77 Epub 2011 Aug 1; Authors: Kossenkov AV, Vachani A, Chang C, Nichols C, Billouin S, Horng W, Rom WN, Albelda SM, Showe MK, Showe LC

• Pharmacologic activation of the innate immune system to prevent respiratory viral infections.
  American journal of respiratory cell and molecular biology. 2011 Sep;45(3):480-8 Epub 2010 Dec 10; Authors: Cheng G, Wang LC, Fridlender ZG, Cheng GS, Chen B, Mangalmurti NS, Saloura V, Yu Z, Kapoor V, Mozdzanowska K, Moon E, Sun J, Kreindler JL, Cohen NA, Caton AJ, Erikson J, Albelda SM

• Targeted endothelial delivery of nanosized catalase immunoconjugates protects lung grafts donated after cardiac death.
  Transplantation. 2011 Aug 27;92(4):380-7; Authors: Preissler G, Loehe F, Huff IV, Ebersberger U, Shuvaev VV, Bittmann I, Hermanns I, Kirkpatrick JC, Fischer K, Eichhorn ME, Winter H, Jauch KW, Albelda SM, Muzykantov VR, Wiewrodt R

• Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2011 Jul 15;17(14):4719-30 Epub 2011 May 24; Authors: Moon EK, Carpenito C, Sun J, Wang LC, Kapoor V, Predina J, Powell DJ Jr, Riley JL, June CH, Albelda SM

• The junctional adhesion molecule JAM-C regulates polarized transendothelial migration of neutrophils in vivo.
  Nature immunology. 2011 Jun 26;12(8):761-9; Authors: Woodfin A, Voisin MB, Beyrau M, Colom B, Caille D, Diapouli FM, Nash GB, Chavakis T, Albelda SM, Rainger GE, Meda P, Imhof BA, Nourshargh S

• Gene therapy for mesothelioma.
  Current treatment options in oncology. 2011 Jun;12(2):173-80; Authors: Vachani A, Moon E, Albelda SM

• Novel variants in the PRDX6 Gene and the risk of Acute Lung Injury following major trauma.
  BMC medical genetics. 2011 May 31;12:77; Authors: Rushefski M, Aplenc R, Meyer N, Li M, Feng R, Lanken PN, Gallop R, Bellamy S, Localio AR, Feinstein SI, Fisher AB, Albelda SM, Christie JD

• ANGPT2 genetic variant is associated with trauma-associated acute lung injury and altered plasma angiopoietin-2 isoform ratio.
  American journal of respiratory and critical care medicine. 2011 May 15;183(10):1344-53 Epub 2011 Jan 21; Authors: Meyer NJ, Li M, Feng R, Bradfield J, Gallop R, Bellamy S, Fuchs BD, Lanken PN, Albelda SM, Rushefski M, Aplenc R, Abramova H, Atochina-Vasserman EN, Beers MF, Calfee CS, Cohen MJ, Pittet JF, Christiani DC, O'Keefe GE, Ware LB, May AK, Wurfel MM, Hakonarson H, Christie JD

• Modulation of endothelial targeting by size of antibody-antioxidant enzyme conjugates.
  Journal of controlled release : official journal of the Controlled Release Society. 2011 Feb 10;149(3):236-41 Epub 2010 Oct 31; Authors: Shuvaev VV, Tliba S, Pick J, Arguiri E, Christofidou-Solomidou M, Albelda SM, Muzykantov VR

• Monocyte chemoattractant protein-1 blockade inhibits lung cancer tumor growth by altering macrophage phenotype and activating CD8+ cells.
  American journal of respiratory cell and molecular biology. 2011 Feb;44(2):230-7 Epub 2010 Apr 15; Authors: Fridlender ZG, Kapoor V, Buchlis G, Cheng G, Sun J, Wang LC, Singhal S, Snyder LA, Albelda SM

• Vesicular stomatitis virus-induced immune suppressor cells generate antagonism between intratumoral oncolytic virus and cyclophosphamide.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2011 Jan;19(1):140-9 Epub 2010 Oct 26; Authors: Willmon C, Diaz RM, Wongthida P, Galivo F, Kottke T, Thompson J, Albelda S, Harrington K, Melcher A, Vile R

• Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
  Cancer research. 2010 Nov 15;70(22):9053-61 Epub 2010 Oct 5; Authors: Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH

• Advanced glycation end products on stored red blood cells increase endothelial reactive oxygen species generation through interaction with receptor for advanced glycation end products.
  Transfusion. 2010 Nov;50(11):2353-61; Authors: Mangalmurti NS, Chatterjee S, Cheng G, Andersen E, Mohammed A, Siegel DL, Schmidt AM, Albelda SM, Lee JS

• Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2010 Nov;18(11):1947-59 Epub 2010 Aug 3; Authors: Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, Albelda SM

• Preclinical evidence for a beneficial impact of valproate on the response of small cell lung cancer to first-line chemotherapy.
  European journal of cancer (Oxford, England : 1990). 2010 Jun;46(9):1724-34 Epub 2010 May 5; Authors: Hubaux R, Vandermeers F, Crisanti MC, Kapoor V, Burny A, Mascaux C, Albelda SM, Willems L

• Activation of the nucleotide oligomerization domain signaling pathway by the non-bacterially derived xanthone drug 5'6-dimethylxanthenone-4-acetic acid (Vadimezan).
  The Journal of biological chemistry. 2010 Apr 2;285(14):10553-62 Epub 2010 Jan 29; Authors: Cheng G, Sun J, Fridlender ZG, Wang LC, Ching LM, Albelda SM

• A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2010 Apr;18(4):852-60 Epub 2010 Jan 12; Authors: Sterman DH, Recio A, Haas AR, Vachani A, Katz SI, Gillespie CT, Cheng G, Sun J, Moon E, Pereira L, Wang X, Heitjan DF, Litzky L, June CH, Vonderheide RH, Carroll RG, Albelda SM

• Gene therapy for mesothelioma and lung cancer.
  American journal of respiratory cell and molecular biology. 2010 Apr;42(4):385-93 Epub 2010 Feb 16; Authors: Vachani A, Moon E, Wakeam E, Albelda SM

• Urinary volatile compounds as biomarkers for lung cancer: a proof of principle study using odor signatures in mouse models of lung cancer.
  PloS one. 2010 Jan 27;5(1):e8819; Authors: Matsumura K, Opiekun M, Oka H, Vachani A, Albelda SM, Yamazaki K, Beauchamp GK

• Evaluation of an attenuated vesicular stomatitis virus vector expressing interferon-beta for use in malignant pleural mesothelioma: heterogeneity in interferon responsiveness defines potential efficacy.
  Human gene therapy. 2010 Jan;21(1):51-64; Authors: Saloura V, Wang LC, Fridlender ZG, Sun J, Cheng G, Kapoor V, Sterman DH, Harty RN, Okumura A, Barber GN, Vile RG, Federspiel MJ, Russell SJ, Litzky L, Albelda SM

• CCL2 blockade augments cancer immunotherapy.
  Cancer research. 2010 Jan 1;70(1):109-18 Epub 2009 Dec 22; Authors: Fridlender ZG, Buchlis G, Kapoor V, Cheng G, Sun J, Singhal S, Crisanti MC, Wang LC, Heitjan D, Snyder LA, Albelda SM

• Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease.
  Cancer research. 2009 Dec 15;69(24):9202-10; Authors: Showe MK, Vachani A, Kossenkov AV, Yousef M, Nichols C, Nikonova EV, Chang C, Kucharczuk J, Tran B, Wakeam E, Yie TA, Speicher D, Rom WN, Albelda S, Showe LC

• Targeted detoxification of selected reactive oxygen species in the vascular endothelium.
  The Journal of pharmacology and experimental therapeutics. 2009 Nov;331(2):404-11 Epub 2009 Aug 19; Authors: Shuvaev VV, Christofidou-Solomidou M, Bhora F, Laude K, Cai H, Dikalov S, Arguiri E, Solomides CC, Albelda SM, Harrison DG, Muzykantov VR

• Expression of IFN-beta enhances both efficacy and safety of oncolytic vesicular stomatitis virus for therapy of mesothelioma.
  Cancer research. 2009 Oct 1;69(19):7713-20 Epub 2009 Sep 22; Authors: Willmon CL, Saloura V, Fridlender ZG, Wongthida P, Diaz RM, Thompson J, Kottke T, Federspiel M, Barber G, Albelda SM, Vile RG

• Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.
  Cancer cell. 2009 Sep 8;16(3):183-94; Authors: Fridlender ZG, Sun J, Kim S, Kapoor V, Cheng G, Ling L, Worthen GS, Albelda SM

• Anchoring fusion thrombomodulin to the endothelial lumen protects against injury-induced lung thrombosis and inflammation.
  American journal of respiratory and critical care medicine. 2009 Aug 1;180(3):247-56 Epub 2009 Apr 2; Authors: Ding BS, Hong N, Christofidou-Solomidou M, Gottstein C, Albelda SM, Cines DB, Fisher AB, Muzykantov VR

• The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer.
  Molecular cancer therapeutics. 2009 Aug;8(8):2221-31 Epub 2009 Aug 11; Authors: Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD, Albelda SM

• Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment.
  American journal of respiratory and critical care medicine. 2009 May 15;179(10):950-4 Epub 2009 Feb 6; Authors: Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A

• Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.
  Proceedings of the National Academy of Sciences of the United States of America. 2009 Mar 3;106(9):3360-5 Epub 2009 Feb 11; Authors: Carpenito C, Milone MC, Hassan R, Simonet JC, Lakhal M, Suhoski MM, Varela-Rohena A, Haines KM, Heitjan DF, Albelda SM, Carroll RG, Riley JL, Pastan I, June CH

• Systemic blockade of transforming growth factor-beta signaling augments the efficacy of immunogene therapy.
  Cancer research. 2008 Dec 15;68(24):10247-56; Authors: Kim S, Buchlis G, Fridlender ZG, Sun J, Kapoor V, Cheng G, Haas A, Cheung HK, Zhang X, Corbley M, Kaiser LR, Ling L, Albelda SM

• Variation in the myosin light chain kinase gene is associated with development of acute lung injury after major trauma.
  Critical care medicine. 2008 Oct;36(10):2794-800; Authors: Christie JD, Ma SF, Aplenc R, Li M, Lanken PN, Shah CV, Fuchs B, Albelda SM, Flores C, Garcia JG

• Distinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cells.
  PloS one. 2008 Sep 26;3(9):e3289; Authors: Carroll RG, Carpenito C, Shan X, Danet-Desnoyers G, Liu R, Jiang S, Albelda SM, Golovina T, Coukos G, Riley JL, Jonak ZL, June CH

• Differential intra-endothelial delivery of polymer nanocarriers targeted to distinct PECAM-1 epitopes.
  Journal of controlled release : official journal of the Controlled Release Society. 2008 Sep 24;130(3):226-33 Epub 2008 Jun 18; Authors: Garnacho C, Albelda SM, Muzykantov VR, Muro S

• Transforming growth factor-beta receptor blockade augments the effectiveness of adoptive T-cell therapy of established solid cancers.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2008 Jun 15;14(12):3966-74; Authors: Wallace A, Kapoor V, Sun J, Mrass P, Weninger W, Heitjan DF, June C, Kaiser LR, Ling LE, Albelda SM

• B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models.
  Journal of immunotherapy (Hagerstown, Md. : 1997). 2008 Jun;31(5):446-57; Authors: Kim S, Fridlender ZG, Dunn R, Kehry MR, Kapoor V, Blouin A, Kaiser LR, Albelda SM

• RhoA activation and actin reorganization involved in endothelial CAM-mediated endocytosis of anti-PECAM carriers: critical role for tyrosine 686 in the cytoplasmic tail of PECAM-1.
  Blood. 2008 Mar 15;111(6):3024-33 Epub 2008 Jan 8; Authors: Garnacho C, Shuvaev V, Thomas A, McKenna L, Sun J, Koval M, Albelda S, Muzykantov V, Muro S

• Prophylactic thrombolysis by thrombin-activated latent prourokinase targeted to PECAM-1 in the pulmonary vasculature.
  Blood. 2008 Feb 15;111(4):1999-2006 Epub 2007 Nov 28; Authors: Ding BS, Hong N, Murciano JC, Ganguly K, Gottstein C, Christofidou-Solomidou M, Albelda SM, Fisher AB, Cines DB, Muzykantov VR

• Endothelial targeting of semi-permeable polymer nanocarriers for enzyme therapies.
  Biomaterials. 2008 Jan;29(2):215-27 Epub 2007 Oct 24; Authors: Dziubla TD, Shuvaev VV, Hong NK, Hawkins BJ, Madesh M, Takano H, Simone E, Nakada MT, Fisher A, Albelda SM, Muzykantov VR

• Platelet-endothelial cell adhesion molecule-1-directed endothelial targeting of superoxide dismutase alleviates oxidative stress caused by either extracellular or intracellular superoxide.
  The Journal of pharmacology and experimental therapeutics. 2007 Nov;323(2):450-7 Epub 2007 Aug 21; Authors: Shuvaev VV, Tliba S, Nakada M, Albelda SM, Muzykantov VR

• A phase I clinical trial of single-dose intrapleural IFN-beta gene transfer for malignant pleural mesothelioma and metastatic pleural effusions: high rate of antitumor immune responses.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 Aug 1;13(15 Pt 1):4456-66; Authors: Sterman DH, Recio A, Carroll RG, Gillespie CT, Haas A, Vachani A, Kapoor V, Sun J, Hodinka R, Brown JL, Corbley MJ, Parr M, Ho M, Pastan I, Machuzak M, Benedict W, Zhang XQ, Lord EM, Litzky LA, Heitjan DF, June CH, Kaiser LR, Vonderheide RH, Albelda SM, Kanther M

• Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.
  Journal of immunology (Baltimore, Md. : 1950). 2007 Jul 15;179(2):977-83; Authors: Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S

• The vascular disrupting agent, DMXAA, directly activates dendritic cells through a MyD88-independent mechanism and generates antitumor cytotoxic T lymphocytes.
  Cancer research. 2007 Jul 15;67(14):7011-9; Authors: Wallace A, LaRosa DF, Kapoor V, Sun J, Cheng G, Jassar A, Blouin A, Ching LM, Albelda SM

• Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects.
  Cancer biology & therapy. 2007 Jun;6(6):880-5 Epub 2007 Mar 1; Authors: Suzuki E, Sun J, Kapoor V, Jassar AS, Albelda SM

• A 10-gene classifier for distinguishing head and neck squamous cell carcinoma and lung squamous cell carcinoma.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2007 May 15;13(10):2905-15; Authors: Vachani A, Nebozhyn M, Singhal S, Alila L, Wakeam E, Muschel R, Powell CA, Gaffney P, Singh B, Brose MS, Litzky LA, Kucharczuk J, Kaiser LR, Marron JS, Showe MK, Albelda SM, Showe LC

• Factors modulating the delivery and effect of enzymatic cargo conjugated with antibodies targeted to the pulmonary endothelium.
  Journal of controlled release : official journal of the Controlled Release Society. 2007 Apr 2;118(2):235-44 Epub 2007 Jan 8; Authors: Shuvaev VV, Christofidou-Solomidou M, Scherpereel A, Simone E, Arguiri E, Tliba S, Pick J, Kennel S, Albelda SM, Muzykantov VR

• Cytokine gene therapy for malignant pleural mesothelioma.
  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2007 Apr;2(4):265-7; Authors: Vachani A, Sterman DH, Albelda SM

• A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
  Cancer research. 2007 Mar 1;67(5):2351-9; Authors: Suzuki E, Kim S, Cheung HK, Corbley MJ, Zhang X, Sun L, Shan F, Singh J, Lee WC, Albelda SM, Ling LE

• Dissociation between alveolar transmigration of neutrophils and lung injury in hyperoxia.
  American journal of physiology. Lung cellular and molecular physiology. 2006 Nov;291(5):L1050-8 Epub 2006 Jun 30; Authors: Perkowski S, Scherpereel A, Murciano JC, Arguiri E, Solomides CC, Albelda SM, Muzykantov V, Christofidou-Solomidou M

• Interferon beta adenoviral gene therapy in a patient with ovarian cancer.
  Nature clinical practice. Oncology. 2006 Nov;3(11):633-9; Authors: Sterman DH, Gillespie CT, Carroll RG, Coughlin CM, Lord EM, Sun J, Haas A, Recio A, Kaiser LR, Coukos G, June CH, Albelda SM, Vonderheide RH

• Blockade of TNF-alpha decreases both inflammation and efficacy of intrapulmonary Ad.IFNbeta immunotherapy in an orthotopic model of bronchogenic lung cancer.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2006 May;13(5):910-7 Epub 2006 Feb 17; Authors: Wilderman MJ, Kim S, Gillespie CT, Sun J, Kapoor V, Vachani A, Sterman DH, Kaiser LR, Albelda SM

• Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2006 Jan 1;12(1):214-22; Authors: Haas AR, Sun J, Vachani A, Wallace AF, Silverberg M, Kapoor V, Albelda SM

• Endothelial targeting of a recombinant construct fusing a PECAM-1 single-chain variable antibody fragment (scFv) with prourokinase facilitates prophylactic thrombolysis in the pulmonary vasculature.
  Blood. 2005 Dec 15;106(13):4191-8 Epub 2005 Sep 6; Authors: Ding BS, Gottstein C, Grunow A, Kuo A, Ganguly K, Albelda SM, Cines DB, Muzykantov VR

• Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
  Cancer research. 2005 Dec 15;65(24):11752-61; Authors: Jassar AS, Suzuki E, Kapoor V, Sun J, Silverberg MB, Cheung L, Burdick MD, Strieter RM, Ching LM, Kaiser LR, Albelda SM

• Long-term follow-up of patients with malignant pleural mesothelioma receiving high-dose adenovirus herpes simplex thymidine kinase/ganciclovir suicide gene therapy.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Oct 15;11(20):7444-53; Authors: Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P, Amin KM, Litzky LA, Wilson JM, Kaiser LR, Albelda SM

• Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung.
  Cancer research. 2005 Sep 15;65(18):8379-87; Authors: Wilderman MJ, Sun J, Jassar AS, Kapoor V, Khan M, Vachani A, Suzuki E, Kinniry PA, Sterman DH, Kaiser LR, Albelda SM

• Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Sep 15;11(18):6713-21; Authors: Suzuki E, Kapoor V, Jassar AS, Kaiser LR, Albelda SM

• Prognostic implications of cell cycle, apoptosis, and angiogenesis biomarkers in non-small cell lung cancer: a review.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Jun 1;11(11):3974-86; Authors: Singhal S, Vachani A, Antin-Ozerkis D, Kaiser LR, Albelda SM

• Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma.
  Respirology (Carlton, Vic.). 2005 Jun;10(3):266-83; Authors: Sterman DH, Albelda SM

• Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma.
  Cancer biology & therapy. 2005 Mar;4(3):342-6 Epub 2005 Mar 1; Authors: DeLong P, Carroll RG, Henry AC, Tanaka T, Ahmad S, Leibowitz MS, Sterman DH, June CH, Albelda SM, Vonderheide RH

• Treatment of lung cancer using clinically relevant oral doses of the cyclooxygenase-2 inhibitor rofecoxib: potential value as adjuvant therapy after surgery.
  Annals of surgery. 2005 Jan;241(1):168-78; Authors: Tanaka T, Delong PA, Amin K, Henry A, Kruklitis R, Kapoor V, Kaiser LR, Albelda SM

• Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2004 Sep 1;10(17):5907-18; Authors: Suzuki E, Kapoor V, Cheung HK, Ling LE, DeLong PA, Kaiser LR, Albelda SM

• Role of lateral cell-cell border location and extracellular/transmembrane domains in PECAM/CD31 mechanosensation.
  Biochemical and biophysical research communications. 2004 Aug 6;320(4):1076-81; Authors: Kaufman DA, Albelda SM, Sun J, Davies PF

• Role for platelet-endothelial cell adhesion molecule-1 in macrophage Fcgamma receptor function.
  American journal of respiratory cell and molecular biology. 2004 Aug;31(2):246-55 Epub 2004 Apr 15; Authors: Albelda SM, Lau KC, Chien P, Huang ZY, Arguiris E, Bohen A, Sun J, Billet JA, Christofidou-Solomidou M, Indik ZK, Schreiber AD

• TNFerade to the rescue? Guidelines for evaluating phase I cancer gene transfer trials.
  Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Feb 15;22(4):577-9 Epub 2004 Jan 15; Authors: Albelda SM, Sterman DH

• Immuno-gene therapy with interferon-beta before surgical debulking delays recurrence and improves survival in a murine model of malignant mesothelioma.
  The Journal of thoracic and cardiovascular surgery. 2004 Jan;127(1):123-30; Authors: Kruklitis RJ, Singhal S, Delong P, Kapoor V, Sterman DH, Kaiser LR, Albelda SM

• Use of cyclooxygenase-2 inhibition to enhance the efficacy of immunotherapy.
  Cancer research. 2003 Nov 15;63(22):7845-52; Authors: DeLong P, Tanaka T, Kruklitis R, Henry AC, Kapoor V, Kaiser LR, Sterman DH, Albelda SM

• Differentially expressed apoptotic genes in early stage lung adenocarcinoma predicted by expression profiling.
  Cancer biology & therapy. 2003 Sep-Oct;2(5):566-71; Authors: Singhal S, Amin KM, Kruklitis R, Marshall MB, Kucharczuk JC, DeLong P, Litzky LA, Kaiser LR, Albelda SM

• PECAM-directed delivery of catalase to endothelium protects against pulmonary vascular oxidative stress.
  American journal of physiology. Lung cellular and molecular physiology. 2003 Aug;285(2):L283-92; Authors: Christofidou-Solomidou M, Scherpereel A, Wiewrodt R, Ng K, Sweitzer T, Arguiri E, Shuvaev V, Solomides CC, Albelda SM, Muzykantov VR

• Gene expression profiling of malignant mesothelioma.
  Clinical cancer research : an official journal of the American Association for Cancer Research. 2003 Aug 1;9(8):3080-97; Authors: Singhal S, Wiewrodt R, Malden LD, Amin KM, Matzie K, Friedberg J, Kucharczuk JC, Litzky LA, Johnson SW, Kaiser LR, Albelda SM

• PECAM-1 functions as a specific and potent inhibitor of mitochondrial-dependent apoptosis.
  Blood. 2003 Jul 1;102(1):169-79 Epub 2003 Mar 20; Authors: Gao C, Sun W, Christofidou-Solomidou M, Sawada M, Newman DK, Bergom C, Albelda SM, Matsuyama S, Newman PJ

• Microarray data simulator for improved selection of differentially expressed genes.
  Cancer biology & therapy. 2003 Jul-Aug;2(4):383-91; Authors: Singhal S, Kyvernitis CG, Johnson SW, Kaiser LR, Liebman MN, Albelda SM

• Gene expression profiling of the early pulmonary response to hyperoxia in mice.
  American journal of respiratory cell and molecular biology. 2003 Jun;28(6):682-96; Authors: Perkowski S, Sun J, Singhal S, Santiago J, Leikauf GD, Albelda SM

• ICAM-directed vascular immunotargeting of antithrombotic agents to the endothelial luminal surface.
  Blood. 2003 May 15;101(10):3977-84 Epub 2003 Jan 16; Authors: Murciano JC, Muro S, Koniaris L, Christofidou-Solomidou M, Harshaw DW, Albelda SM, Granger DN, Cines DB, Muzykantov VR

• Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
  Cancer gene therapy. 2003 May;10(5):353-64; Authors: Wiewrodt R, Amin K, Kiefer M, Jovanovic VP, Kapoor V, Force S, Chang M, Lanuti M, Black ME, Kaiser LR, Albelda SM

• Alterations in cell cycle genes in early stage lung adenocarcinoma identified by expression profiling.
  Cancer biology & therapy. 2003 May-Jun;2(3):291-8; Authors: Singhal S, Amin KM, Kruklitis R, DeLong P, Friscia ME, Litzky LA, Putt ME, Kaiser LR, Albelda SM

• A novel endocytic pathway induced by clustering endothelial ICAM-1 or PECAM-1.
  Journal of cell science. 2003 Apr 15;116(Pt 8):1599-609; Authors: Muro S, Wiewrodt R, Thomas A, Koniaris L, Albelda SM, Muzykantov VR, Koval M

• Immunotargeting of catalase to the pulmonary endothelium alleviates oxidative stress and reduces acute lung transplantation injury.
  Nature biotechnology. 2003 Apr;21(4):392-8 Epub 2003 Mar 24; Authors: Kozower BD, Christofidou-Solomidou M, Sweitzer TD, Muro S, Buerk DG, Solomides CC, Albelda SM, Patterson GA, Muzykantov VR

• PECAM-1-dependent neutrophil transmigration is independent of monolayer PECAM-1 signaling or localization.
  Blood. 2003 Apr 1;101(7):2816-25 Epub 2002 Dec 5; Authors: O'Brien CD, Lim P, Sun J, Albelda SM

• Platelet endothelial cell adhesion molecule-1 in neutrophil emigration during acute bacterial pneumonia in mice and rats.
  American journal of respiratory and critical care medicine. 2003 Jan 15;167(2):164-70; Authors: Tasaka S, Qin L, Saijo A, Albelda SM, DeLisser HM, Doerschuk CM

• BRAF and RAS mutations in human lung cancer and melanoma.
  Cancer research. 2002 Dec 1;62(23):6997-7000; Authors: Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal PA, Wooster R, Stratton MR, Weber BL

• Analysis of the immunologic response generated by Ad.IFN-beta during successful intraperitoneal tumor gene therapy.
  Molecular therapy : the journal of the American Society of Gene Therapy. 2002 Aug;6(2):210-8; Authors: Odaka M, Wiewrodt R, DeLong P, Tanaka T, Zhang Y, Kaiser L, Albelda S

• PECAM-1 (CD31) regulates a hydrogen peroxide-activated nonselective cation channel in endothelial cells.
  The Journal of cell biology. 2002 Apr 1;157(1):173-84; Authors: Ji G, O'Brien CD, Feldman M, Manevich Y, Lim P, Sun J, Albelda SM, Kotlikoff MI

• Replication-selective herpes simplex virus type 1 mutant therapy of cervical cancer is enhanced by low-dose radiation.
  Human gene therapy. 2002 Mar 20;13(5):627-39; Authors: Blank SV, Rubin SC, Coukos G, Amin KM, Albelda SM, Molnar-Kimber KL

• Platelet-endothelial cell adhesion molecule-1-directed immunotargeting to cardiopulmonary vasculature.
  The Journal of pharmacology and experimental therapeutics. 2002 Mar;300(3):777-86; Authors: Scherpereel A, Rome JJ, Wiewrodt R, Watkins SC, Harshaw DW, Alder S, Christofidou-Solomidou M, Haut E, Murciano JC, Nakada M, Albelda SM, Muzykantov VR

• Vascular immunotargeting of glucose oxidase to the endothelial antigens induces distinct forms of oxidant acute lung injury: targeting to thrombomodulin, but not to PECAM-1, causes pulmonary thrombosis and neutrophil transmigration.
  The American journal of pathology. 2002 Mar;160(3):1155-69; Authors: Christofidou-Solomidou M, Kennel S, Scherpereel A, Wiewrodt R, Solomides CC, Pietra GG, Murciano JC, Shah SA, Ischiropoulos H, Albelda SM, Muzykantov VR

• Pulmonary genetics, genomics, and gene therapy: conference summary.
  Chest. 2002 Mar;121(3 Suppl):105S-110S; Authors: Albelda SM

• Gene therapy for lung neoplasms.
  Clinics in chest medicine. 2002 Mar;23(1):265-77; Authors: Albelda SM, Wiewrodt R, Sterman DH

• Size-dependent intracellular immunotargeting of therapeutic cargoes into endothelial cells.
  Blood. 2002 Feb 1;99(3):912-22; Authors: Wiewrodt R, Thomas AP, Cipelletti L, Christofidou-Solomidou M, Weitz DA, Feinstein SI, Schaffer D, Albelda SM, Koval M, Muzykantov VR

• Detection of SV40 DNA sequences in malignant mesothelioma specimens from the United States, but not from Turkey.
  Journal of cellular biochemistry. 2002;84(3):455-9; Authors: De Rienzo A, Tor M, Sterman DH, Aksoy F, Albelda SM, Testa JR